423 related articles for article (PubMed ID: 23172833)
1. Combined application of cytology and molecular urine markers to improve the detection of urothelial carcinoma.
Todenhöfer T; Hennenlotter J; Esser M; Mohrhardt S; Tews V; Aufderklamm S; Gakis G; Kuehs U; Stenzl A; Schwentner C
Cancer Cytopathol; 2013 May; 121(5):252-60. PubMed ID: 23172833
[TBL] [Abstract][Full Text] [Related]
2. Impact of different grades of microscopic hematuria on the performance of urine-based markers for the detection of urothelial carcinoma.
Todenhöfer T; Hennenlotter J; Tews V; Gakis G; Aufderklamm S; Kuehs U; Stenzl A; Schwentner C
Urol Oncol; 2013 Oct; 31(7):1148-54. PubMed ID: 22130125
[TBL] [Abstract][Full Text] [Related]
3. Combinations of urine-based tumour markers in bladder cancer surveillance.
Horstmann M; Patschan O; Hennenlotter J; Senger E; Feil G; Stenzl A
Scand J Urol Nephrol; 2009; 43(6):461-6. PubMed ID: 19903092
[TBL] [Abstract][Full Text] [Related]
4. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice.
May M; Hakenberg OW; Gunia S; Pohling P; Helke C; Lübbe L; Nowack R; Siegsmund M; Hoschke B
Urology; 2007 Sep; 70(3):449-53. PubMed ID: 17688921
[TBL] [Abstract][Full Text] [Related]
5. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
Kumar A; Kumar R; Gupta NP
Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of fluorescence in situ hybridization as an ancillary tool to urine cytology in diagnosing urothelial carcinoma.
Veeramachaneni R; Nordberg ML; Shi R; Herrera GA; Turbat-Herrera EA
Diagn Cytopathol; 2003 Jun; 28(6):301-7. PubMed ID: 12768634
[TBL] [Abstract][Full Text] [Related]
7. The use of urinary nuclear matrix protein 22 (NMP22) as a diagnostic adjunct to urine cytology for monitoring of recurrent bladder cancer--institutional experience and review.
Önal B; Han Ü; Yilmaz S; Köybasioglu F; Altuğ U
Diagn Cytopathol; 2015 Apr; 43(4):307-14. PubMed ID: 25488052
[TBL] [Abstract][Full Text] [Related]
8. Fluorescence in situ hybridization assay detects upper urinary tract transitional cell carcinoma in patients with asymptomatic hematuria and negative urine cytology.
Huang WT; Li LY; Pang J; Ruan XX; Sun QP; Yang WJ; Gao X
Neoplasma; 2012; 59(4):355-60. PubMed ID: 22489689
[TBL] [Abstract][Full Text] [Related]
9. A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria.
O'Sullivan P; Sharples K; Dalphin M; Davidson P; Gilling P; Cambridge L; Harvey J; Toro T; Giles N; Luxmanan C; Alves CF; Yoon HS; Hinder V; Masters J; Kennedy-Smith A; Beaven T; Guilford PJ
J Urol; 2012 Sep; 188(3):741-7. PubMed ID: 22818138
[TBL] [Abstract][Full Text] [Related]
10. Comparison of fluorescence in situ hybridization, NMP22 bladderchek, and urinary liquid-based cytology in the detection of bladder urothelial carcinoma.
Li HX; Wang MR; Zhao H; Cao J; Li CL; Pan QJ
Diagn Cytopathol; 2013 Oct; 41(10):852-7. PubMed ID: 23444210
[TBL] [Abstract][Full Text] [Related]
11. uCyt+/ImmunoCyt and cytology in the detection of urothelial carcinoma: an update on 7422 analyses.
Comploj E; Mian C; Ambrosini-Spaltro A; Dechet C; Palermo S; Trenti E; Lodde M; Horninger W; Pycha A
Cancer Cytopathol; 2013 Jul; 121(7):392-7. PubMed ID: 23495066
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of NMP22 as an adjunct to a typical urine cytology and low-grade urothelial carcinoma.
Arora VK; Sarungbam J; Bhatia A; Singh N; Agrawal V; Aggarwal S
Diagn Cytopathol; 2010 Nov; 38(11):788-90. PubMed ID: 20014314
[TBL] [Abstract][Full Text] [Related]
13. Influence of urinary tract instrumentation and inflammation on the performance of urine markers for the detection of bladder cancer.
Todenhöfer T; Hennenlotter J; Kühs U; Tews V; Gakis G; Aufderklamm S; Stenzl A; Schwentner C
Urology; 2012 Mar; 79(3):620-4. PubMed ID: 22386412
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the sensitivity and specificity of urine cytology, urinary nuclear matrix protein-22 and multitarget fluorescence in situ hybridization assay in the detection of bladder cancer.
Kehinde EO; Al-Mulla F; Kapila K; Anim JT
Scand J Urol Nephrol; 2011 Mar; 45(2):113-21. PubMed ID: 21091091
[TBL] [Abstract][Full Text] [Related]
15. Urinary NMP22 BladderChek test in the diagnosis of superficial bladder cancer.
Moonen PM; Kiemeney LA; Witjes JA
Eur Urol; 2005 Dec; 48(6):951-6; discussion 956. PubMed ID: 16257108
[TBL] [Abstract][Full Text] [Related]
16. Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study.
Pfister C; Chautard D; Devonec M; Perrin P; Chopin D; Rischmann P; Bouchot O; Beurton D; Coulange C; Rambeaud JJ
J Urol; 2003 Mar; 169(3):921-4. PubMed ID: 12576813
[TBL] [Abstract][Full Text] [Related]
17. Analysis of fluorescence in situ hybridization, mtDNA quantification, and mtDNA sequence for the detection of early bladder cancer.
Yoo JH; Suh B; Park TS; Shin MG; Choi YD; Lee CH; Choi JR
Cancer Genet Cytogenet; 2010 Apr; 198(2):107-17. PubMed ID: 20362225
[TBL] [Abstract][Full Text] [Related]
18. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
19. Fluorescence in situ hybridization (FISH) in the diagnosis of bladder and upper tract urothelial carcinoma: the largest single-institution experience to date.
Gomella LG; Mann MJ; Cleary RC; Hubosky SG; Bagley DH; Thumar AB; McCue PA; Lallas CD; Trabulsi EJ
Can J Urol; 2017 Feb; 24(1):8620-8626. PubMed ID: 28263126
[TBL] [Abstract][Full Text] [Related]
20. Urinary survivin mRNA expression and urinary nuclear matrix protein 22 BladderChek® and urine cytology in the detection of transitional cell carcinoma of the bladder.
Al-Maghrebi M; Kehinde EO; Kapila K; Anim JT
Med Princ Pract; 2012; 21(3):295-7. PubMed ID: 22236881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]